WO1998036744A1 - Use of milnacipran and its derivatives for preparing a medicine for treating certain psychiatric diseases - Google Patents

Use of milnacipran and its derivatives for preparing a medicine for treating certain psychiatric diseases Download PDF

Info

Publication number
WO1998036744A1
WO1998036744A1 PCT/FR1998/000320 FR9800320W WO9836744A1 WO 1998036744 A1 WO1998036744 A1 WO 1998036744A1 FR 9800320 W FR9800320 W FR 9800320W WO 9836744 A1 WO9836744 A1 WO 9836744A1
Authority
WO
WIPO (PCT)
Prior art keywords
milnacipran
disorders
patients
medicine
preparing
Prior art date
Application number
PCT/FR1998/000320
Other languages
French (fr)
Inventor
Michael Briley
Jean-François Prost
Original Assignee
Pierre Fabre Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pierre Fabre Medicament filed Critical Pierre Fabre Medicament
Priority to AU64060/98A priority Critical patent/AU6406098A/en
Publication of WO1998036744A1 publication Critical patent/WO1998036744A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide

Definitions

  • milnacipran and its derivatives for the preparation of a medicament intended for the treatment of certain psychiatric diseases
  • the present invention relates to the use of milnacipran for the preparation of a medicament intended for the treatment of certain psychiatric diseases such as panic attacks, post-traumatic disorders, social phobia, obsessive-compulsive disorders, drug addiction, sleep disturbances, premenstrual dysphoric disorders and eating disorders.
  • certain psychiatric diseases such as panic attacks, post-traumatic disorders, social phobia, obsessive-compulsive disorders, drug addiction, sleep disturbances, premenstrual dysphoric disorders and eating disorders.
  • Panic attacks are conventionally treated with alprazolam, obsessive compulsive disorder with clomipramine and sleep disorder with benzodiazepines. No treatment is recommended in the case of premenstrual dysphoric disorders and drug addiction.
  • post-traumatic disorders social phobia, bulimia and anorexia
  • the prescription of a tricyclic antidepressant or a serotonin reuptake inhibitor has already been proposed (Goodman & Gilman 's The Pharmacological Basis of Therapeutics 9th Ed. (1995), Hardman JG, Linbird LE, Molinof PB, Ruddon RW, Goodman Gilman A., Ed. McGraw-Hil, New York).
  • n of formula 1,
  • the milnacipran used can be dextrorotatory, levorotatory or a mixture of the two isomers in any proportion, including the racemic mixture.
  • Dosage form used 25 or 50 g capsule
  • Dosage practiced 50 to 300 g / day in two doses morning and evening during the meal. • Panic attacks:
  • milnacipran has been studied in nine patients with obsessive-compulsive disorder, defined according to the criteria of DSM-III. After treatment with doses ranging from 200 to 300 mg / day of milnacipran for periods of the order of two to ten months, six patients had a response considered to be good or excellent with a significant decrease on the YBOC scale and Hamilton's scale of anxiety. Digestive side effects have been reported by four patients, especially at the start of treatment.
  • Twenty-two patients undergoing detoxification (seven from cocaine, four from amphetamines and eleven from alcohol) were treated with milnacipran doses of 50 to 150 mg / day for three to twelve weeks, five in seven of the cocaine addicts, two in four of the addicts and eight in eleven of the addicts reported significant decreases in their craving and a decrease in anxiety as measured by the Hamilton scale, five patients reported nausea at the start treatment but the severity was not sufficient to interrupt treatment.
  • Sleep disorders Milnacipran has been studied in twenty-four patients with primary sleep disorders. Twelve patients suffered from primary insomnia, nine from primary hypersomnia and three from narcolepsy. Their sleep disturbances were confirmed, in all cases, by polysomnography. Milnacipran has been administered in doses ranging from 50 to 200 mg / day for two to six weeks. Symptoms "improved or greatly improved" in nine patients with insomnia, five with hypersomnia and two with narcolepsy. In all cases, regularization of the sleep architecture was observed by polysomnography. According to the patients, one or more of the elements of sleep (sleep continuity, latency of the first period of REM sleep, time to fall asleep) was completely or partially normalized.
  • milnacipran has been studied in twenty-one young women (thirteen anorexics and eight bulimics) having all the diagnostic criteria according to the DSM-IV. Milnacipran has been administered in doses ranging from 50 to 200 mg / day for six to eight weeks. Ten anorexics reported an increase in their body weight as well as a decrease in poor body perception. The few cases of nausea that were reported at the start of treatment did not prevent the continuation of treatment. Four bulimics reported a reduction in periods of excessive feeding (“bingues") with a parallel decrease in the frequency of self-induction of vomiting. One patient, who did not respond, used a large dose of milnacipran (400 mg) to induce vomiting following periods of overeating. No other side effects have been reported.

Abstract

The invention concerns the use of milnacipran for preparing a medicine for treating certain psychiatric diseases such as panic, post-traumatic, obsessional-compusive disorders, drug addiction disintoxication, sleeplessness, pre-menstrual dysphoria and eating disorders.

Description

Utilisation du milnacipran et de ses dérivés pour la préparation d'un médicament destiné au traitement de certaines maladies psychiatriquesUse of milnacipran and its derivatives for the preparation of a medicament intended for the treatment of certain psychiatric diseases
La présente invention concerne l'utilisation du milnacipran pour la préparation d'un médicament destiné au traitement de certaines maladies psychiatriques comme les attaques de panique, les troubles post-traumatiques, la phobie sociale, les troubles obsessionnels-compulsifs, la désintoxication toxicomaniaque, les troubles du sommeil, les troubles dysphoriques prémenstruels et les troubles de l' alimentation.The present invention relates to the use of milnacipran for the preparation of a medicament intended for the treatment of certain psychiatric diseases such as panic attacks, post-traumatic disorders, social phobia, obsessive-compulsive disorders, drug addiction, sleep disturbances, premenstrual dysphoric disorders and eating disorders.
Le traitement de la plupart des maladies psychiatriques précitées a déjà été décrit mais présente souvent une efficacité limitée.The treatment of most of the aforementioned psychiatric diseases has already been described but often has limited effectiveness.
Les attaques de paniques sont traitées classiquement par l' alprazolam, les troubles obsessionnels compulsifs par la clomipramine et les troubles du sommeil par les benzodiazépines. Aucun traitement n'est préconisé dans le cas des troubles dysphoriques prémenstruels et de la désintoxication toxicomaniaque. En ce qui concerne les troubles post-traumatiques, la phobie sociale, la boulimie et l'anorexie, la prescription d'un antidépresseur tricyclique ou d'un inhibiteur de la recapture de la sérotonine a déjà été proposée (Goodman & Gilman' s The Pharmacological Basis of Therapeutics 9th Ed. (1995), Hardman J.G., Linbird L.E., Molinof P.B., Ruddon R.W., Goodman Gilman A., Ed. McGraw-Hil, New York). n, de formule 1,Panic attacks are conventionally treated with alprazolam, obsessive compulsive disorder with clomipramine and sleep disorder with benzodiazepines. No treatment is recommended in the case of premenstrual dysphoric disorders and drug addiction. Regarding post-traumatic disorders, social phobia, bulimia and anorexia, the prescription of a tricyclic antidepressant or a serotonin reuptake inhibitor has already been proposed (Goodman & Gilman 's The Pharmacological Basis of Therapeutics 9th Ed. (1995), Hardman JG, Linbird LE, Molinof PB, Ruddon RW, Goodman Gilman A., Ed. McGraw-Hil, New York). n, of formula 1,
Figure imgf000003_0001
revendiqué dans le brevet FR 81 12312 déposé au nom de la Demanderesse, est un composé nouvellement développé en tant qu'antidépresseur. Son mécanisme d'action original implique l'inhibition sélective de la recapture de la noradrénaline et de la sérotonine sans aucun effet sur les récepteurs post-synaptiques . Pendant le développement clinique du milnacipran, il a été constaté de manière inattendue que l'utilisation du milnacipran permet non seulement de traiter les patients souffrant d'une dépression majeure, mais aussi de traiter d'autres maladies psychiatriques. La présente invention concerne donc l'utilisation du milnacipran pour la préparation d'un médicament destiné au traitement des attaques de panique, troubles post-traumatiques, phobie sociale, troubles obsessionnels-compulsi s, désintoxication toxicomaniaque, troubles du sommeil, troubles dysphoriques prémenstruels et troubles de l'alimentation.
Figure imgf000003_0001
claimed in patent FR 81 12312 filed in the name of the Applicant, is a newly developed compound as an antidepressant. Its original mechanism of action involves the selective inhibition of the reuptake of norepinephrine and serotonin without any effect on the postsynaptic receptors. During the clinical development of milnacipran, it was unexpectedly found that the use of milnacipran not only helps to treat patients with major depression, but also to treat other psychiatric illnesses. The present invention therefore relates to the use of milnacipran for the preparation of a medicament intended for the treatment of panic attacks, post-traumatic disorders, social phobia, obsessive-compulsive disorder, drug addiction, sleep disorders, premenstrual dysphoric disorders and eating disorders.
Le milnacipran utilisé peut être dextrogyre, lévogyre ou un mélange des deux isomères en toute proportion, y compris le mélange racémique.The milnacipran used can be dextrorotatory, levorotatory or a mixture of the two isomers in any proportion, including the racemic mixture.
Etudes cliniquesClinical studies
Forme galénique utilisée : gélule 25 ou 50 g Dosage pratiqué : 50 à 300 g/jour en deux prises matin et soir au cours du repas . • Attaques de panique :Dosage form used: 25 or 50 g capsule Dosage practiced: 50 to 300 g / day in two doses morning and evening during the meal. • Panic attacks:
Dix patients souffrant d'attaques de panique, définies suivant les critères du DSM-III-R, ont reçu 100 à 150 mg/jour de milnacipran pendant huit à douze semaines. Chez sept patients, la réponse était considérée bonne ou excellente avec une diminution de la fréquence et de l'intensité des attaques. Seulement trois patients ont signalé des effets secondaires principalement de nature gastrique.Ten patients with panic attacks, defined according to the DSM-III-R criteria, received 100 to 150 mg / day of milnacipran for eight to twelve weeks. In seven patients, the response was considered good or excellent with a decrease in the frequency and intensity of attacks. Only three patients reported side effects mainly of a gastric nature.
• Troubles post-traumatiques : • Post-traumatic stress disorder:
Patients souffrant de troubles psychiques suite à un événement traumatique (cinq accidents de la circulation graves, deux agressions criminelles, deux viols, un braquage), à qui a été administré le milnacipran à des doses de 50 à 150 mg/jour pendant trois à neuf semaines. Neuf patients rapportaient une nette diminution des souvenirs envahissants ainsi qu'une diminution de leur comportement d'évitement de situations rappelant leur trauma.Patients suffering from mental disorders following a traumatic event (five traffic accidents serious, two criminal assaults, two rapes, one robbery), who was given milnacipran in doses of 50 to 150 mg / day for three to nine weeks. Nine patients reported a clear decrease in pervasive memories as well as a decrease in their behavior to avoid situations reminiscent of their trauma.
• Phobie sociale : Milnacipran, 50 à 200 mg/jour, a été administré pendant trois à dix semaines à treize patients souffrant de phobie sociale suivant la définition du DSM-IV. Neuf patients ont vu leur état s ' améliorer avec notamment une diminution importante de 1 ' anxiété d ' anticipation et du comportement d'évitement des situations sociales. Chez deux patients sur les six ayant souvent des attaques de panique en situation sociale, les attaques ont été éliminées et les autres ont vu leur intensité et leur fréquence se réduire.• Social phobia: Milnacipran, 50 to 200 mg / day, was administered for three to ten weeks to thirteen patients suffering from social phobia as defined by DSM-IV. Nine patients saw their condition improve, notably with a significant reduction in anticipatory anxiety and avoidance behavior in social situations. In two out of six patients who often had panic attacks in a social situation, the attacks were eliminated and the others saw their intensity and frequency reduced.
• Troubles obsessionnels-compulsifs :• Obsessive-compulsive disorder:
L'effet du milnacipran a été étudié chez neuf patients souffrant de troubles obsessionnels-compulsifs, définis suivant les critères du DSM-III. Après traitement à des doses allant de 200 à 300 mg/jour de milnacipran pendant des périodes de l'ordre de deux à dix mois, six patients ont eu une réponse considérée comme bonne ou excellente avec une diminution importante sur l'échelle de YBOC et l'échelle d'Hamilton de l'anxiété. Des effets secondaires digestifs ont été rapportés par quatre patients surtout au début du traitement.The effect of milnacipran has been studied in nine patients with obsessive-compulsive disorder, defined according to the criteria of DSM-III. After treatment with doses ranging from 200 to 300 mg / day of milnacipran for periods of the order of two to ten months, six patients had a response considered to be good or excellent with a significant decrease on the YBOC scale and Hamilton's scale of anxiety. Digestive side effects have been reported by four patients, especially at the start of treatment.
• Désintoxication toxicomaniaque :• Drug addiction detoxification:
Vingt-deux patients en cours de désintoxication (sept de la cocaïne, quatre des amphétaminiques et onze de l'alcool) ont été traités par des doses de milnacipran de 50 à 150 mg/jour pendant trois à douze semaines, cinq sur sept des cocaïnomanes, deux sur quatre des amphétaminomanes et huit sur onze des alcoolomanes ont rapporté des diminutions importantes de leur sensation de manque et une diminution de l'anxiété mesurée par l'échelle d'Hamilton, cinq patients ont signalé des nausées en début de traitement mais la sévérité n'était pas suffisante pour interrompre le traitement.Twenty-two patients undergoing detoxification (seven from cocaine, four from amphetamines and eleven from alcohol) were treated with milnacipran doses of 50 to 150 mg / day for three to twelve weeks, five in seven of the cocaine addicts, two in four of the addicts and eight in eleven of the addicts reported significant decreases in their craving and a decrease in anxiety as measured by the Hamilton scale, five patients reported nausea at the start treatment but the severity was not sufficient to interrupt treatment.
• Troubles du sommeil : Milnacipran a été étudié chez vingt-quatre patients ayant des désordres primaires du sommeil. Douze patients souffraient d'insomnie primaire, neuf d'hypersomnie primaire et trois de narcolepsie. Leurs troubles de sommeil ont été confirmés, dans tous les cas, par polysomnographie. Milnacipran a été administré à des doses allant de 50 à 200 mg/jour pendant deux à six semaines. Les symptômes se sont "améliorés ou très améliorés" chez neuf patients souffrant d'insomnie, cinq patients victimes d'hypersomnie et deux patients atteints de narcolepsie. Dans tous les cas, une régularisation de l'architecture du sommeil a été observée par polysomnographie. Suivant les patients, un ou plusieurs des éléments du sommeil (continuité du sommeil, latence de la première période de sommeil paradoxal, temps d'endormissement) a été normalisé totalement ou partiellement.• Sleep disorders: Milnacipran has been studied in twenty-four patients with primary sleep disorders. Twelve patients suffered from primary insomnia, nine from primary hypersomnia and three from narcolepsy. Their sleep disturbances were confirmed, in all cases, by polysomnography. Milnacipran has been administered in doses ranging from 50 to 200 mg / day for two to six weeks. Symptoms "improved or greatly improved" in nine patients with insomnia, five with hypersomnia and two with narcolepsy. In all cases, regularization of the sleep architecture was observed by polysomnography. According to the patients, one or more of the elements of sleep (sleep continuity, latency of the first period of REM sleep, time to fall asleep) was completely or partially normalized.
• Troubles dysphoriques prémenstruels : • Premenstrual dysphoric disorders:
Onze femmes avec un diagnostic des troubles dysphoriques prémenstruels DSM-IV ont été traitées avec le milnacipran à la dose de 100 mg/jour pendant trois à six mois. Chez neuf femmes, une amélioration générale de l'ensemble de la symptomatologie a été remarquée et en particulier des symptômes associés au manque d'énergie et à la labilité d'affect. Le produit a été bien toléré par 1 'ensemble des patientes traitées . Troubles de l'alimentation :Eleven women diagnosed with premenstrual dysphoric disorder DSM-IV were treated with milnacipran 100 mg / day for three to six months. In nine women, a general improvement in the overall symptomatology was noticed and in particular the symptoms associated with lack of energy and lability of affect. The product was well tolerated by all the patients treated. Eating disorders :
L'effet du milnacipran sur les symptômes de l'anorexie et de la boulimie nerveuses a été étudié chez vingt et un jeunes femmes (treize anorexiques et huit boulimiques) ayant toutes les critères du diagnostic d'après le DSM-IV. Milnacipran a été administré à des doses allant de 50 à 200 mg/jour pendant six à huit semaines. Dix anorexiques ont signalé une augmentation de leur poids corporel ainsi qu'une diminution de la mauvaise perception de leur corps . Les quelques cas de nausée qui ont été rapportés en début de traitement n'ont pas empêché le maintien du traitement. Quatre boulimiques ont rapporté une diminution des périodes d'alimentation excessive ("bingues") avec une diminution parallèle de la fréquence d'auto-induction du vomissement. Une patiente qui n'a pas répondu, a utilisé une forte dose de milnacipran (400 mg) pour se faire vomir suite à des périodes d'alimentation excessive. Aucun autre effet secondaire n'a été signalé. The effect of milnacipran on the symptoms of anorexia and bulimia nervosa has been studied in twenty-one young women (thirteen anorexics and eight bulimics) having all the diagnostic criteria according to the DSM-IV. Milnacipran has been administered in doses ranging from 50 to 200 mg / day for six to eight weeks. Ten anorexics reported an increase in their body weight as well as a decrease in poor body perception. The few cases of nausea that were reported at the start of treatment did not prevent the continuation of treatment. Four bulimics reported a reduction in periods of excessive feeding ("bingues") with a parallel decrease in the frequency of self-induction of vomiting. One patient, who did not respond, used a large dose of milnacipran (400 mg) to induce vomiting following periods of overeating. No other side effects have been reported.

Claims

REVENDICATIONCLAIM
Utilisation du milnacipran pour la préparation d'un médicament destiné au traitement des attaques de panique, troubles post-traumatiques, phobie sociale, troubles obsessionnels-compulsifs, désintoxication toxicomaniaque, troubles du sommeil, troubles dysphoriques prémenstruels et troubles de l'alimentation. Use of milnacipran for the preparation of a medicament intended for the treatment of panic attacks, post-traumatic disorders, social phobia, obsessive-compulsive disorders, drug addiction, sleep disorders, premenstrual dysphoric disorders and eating disorders.
REVENDICATIONS MODIFIEESAMENDED CLAIMS
[reçue par le Bureau International le 31 Juillet 1998 (31.07.98); revendication originale modifiée (1 page)] Utilisation du milnacipran pour la préparation d'un médicament destiné au traitement des troubles post- traumatiques, de la phobie sociale, de la désintoxication toxicomaniaque, des troubles du sommeil, des troubles dysphoriques prémenstruels et des troubles de l'alimentation. [received by the International Bureau on July 31, 1998 (07.31.98); original amended claim (1 page)] Use of milnacipran for the preparation of a medicament for the treatment of post-traumatic disorders, social phobia, drug addiction, sleep disorders, premenstrual dysphoric disorders and food.
PCT/FR1998/000320 1997-02-21 1998-02-19 Use of milnacipran and its derivatives for preparing a medicine for treating certain psychiatric diseases WO1998036744A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU64060/98A AU6406098A (en) 1997-02-21 1998-02-19 Use of minalcipran and its derivatives for preparing a medicine for treating certain psychiatric diseases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9702094A FR2759906B1 (en) 1997-02-21 1997-02-21 USE OF MILNACIPRAN AND DERIVATIVES THEREOF FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF CERTAIN PSYCHIATRIC DISEASES
FR97/02094 1997-02-21

Publications (1)

Publication Number Publication Date
WO1998036744A1 true WO1998036744A1 (en) 1998-08-27

Family

ID=9504033

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR1998/000320 WO1998036744A1 (en) 1997-02-21 1998-02-19 Use of milnacipran and its derivatives for preparing a medicine for treating certain psychiatric diseases

Country Status (3)

Country Link
AU (1) AU6406098A (en)
FR (1) FR2759906B1 (en)
WO (1) WO1998036744A1 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6602911B2 (en) 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
US6635675B2 (en) 2001-11-05 2003-10-21 Cypress Bioscience, Inc. Method of treating chronic fatigue syndrome
WO2007025144A1 (en) * 2005-08-24 2007-03-01 University Of Illinois - Chicago 5-ht2c receptor agonists as anorectic agents
US7345096B2 (en) * 2002-10-15 2008-03-18 Wyeth Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms
KR101185322B1 (en) 2003-02-14 2012-09-21 피에르 파브르 메디카먼트 Use of the enantiomer 1S,2R of milnacipran for the preparation of a medicament
USRE43879E1 (en) 2003-02-14 2012-12-25 Pierre Fabre Medicament Use of the dextrogyral enantiomer of milnacipran for the preparation of a drug

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2779711C (en) 2009-11-06 2016-11-01 Forest Laboratories Holding Limited Novel crystalline forms of (1s,2r)-2-(amino methyl)-n,n-diethyl-1-phenyl cyclopropane carboxamide

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0687472A2 (en) * 1994-06-16 1995-12-20 Eli Lilly And Company Potentiation of drug response by a serotonin 1A receptor antagonist
EP0792649A1 (en) * 1996-02-29 1997-09-03 Eli Lilly And Company Treatment of sleep disorders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0687472A2 (en) * 1994-06-16 1995-12-20 Eli Lilly And Company Potentiation of drug response by a serotonin 1A receptor antagonist
EP0792649A1 (en) * 1996-02-29 1997-09-03 Eli Lilly And Company Treatment of sleep disorders

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ANSSEAU: "Pilot study of milnacipran in panic disorder", EUR. PSYCHIATRY, vol. 6, no. 2, 1991, pages 103 - 106, XP002045908 *
HASHIMOTO: "Serotonin reuptake inhibitors reduce conditioned fear stress-induced freezing behavior in rats", PSYCHOPHARMACOLOGY, vol. 123, no. 2, January 1996 (1996-01-01), pages 182 - 186, XP002045910 *
LOONEN: "Dealing with sadness, madness and hostility", PHARM. WEEKBL. SCI. ED., vol. 14, no. 4a, 1992, pages 206 - 222, XP002045911 *
MORET C ET AL: "BIOCHEMICAL PROFILE OF MIDALCIPRAN (F 2207), 1-PHENYL-U-DIETHYL-AMINOCARBONYL-2-AMINOMETHYL-CYCLOPROPANE (Z) HYDROCHLORIDE, A POTENTIAL FOURTH GENERATION ANTIDEPRESSANT DRUG", NEUROPHARMACOLOGY, vol. 24, no. 12, 1 December 1985 (1985-12-01), pages 1211 - 1219, XP000195985 *
PAPART: "Milnacipran et trouble obsessionnel-compulsif : étude d'un cas", PSYCHIATR. PSYCHOBIOL., vol. 5, no. 5, 1990, pages 325 - 328, XP002045909 *
SERRE: "An early clinical trial of midalcipran, 1-phenyl-1-diethyl aminocarbonyl 2-aminomethyl cyclopropane (Z) hydrochloride, a potential fourth generation antidepressant", CURR. THER. RES., CLIN. EXP., vol. 39, no. 1, 1986, pages 156 - 164, XP002045912 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6602911B2 (en) 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
US6635675B2 (en) 2001-11-05 2003-10-21 Cypress Bioscience, Inc. Method of treating chronic fatigue syndrome
US6992110B2 (en) 2001-11-05 2006-01-31 Cypress Bioscience, Inc. Methods of treating fibromyalgia syndrome, chronic fatigue syndrome and pain
US7345096B2 (en) * 2002-10-15 2008-03-18 Wyeth Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms
KR101185322B1 (en) 2003-02-14 2012-09-21 피에르 파브르 메디카먼트 Use of the enantiomer 1S,2R of milnacipran for the preparation of a medicament
USRE43879E1 (en) 2003-02-14 2012-12-25 Pierre Fabre Medicament Use of the dextrogyral enantiomer of milnacipran for the preparation of a drug
WO2007025144A1 (en) * 2005-08-24 2007-03-01 University Of Illinois - Chicago 5-ht2c receptor agonists as anorectic agents

Also Published As

Publication number Publication date
AU6406098A (en) 1998-09-09
FR2759906B1 (en) 2004-06-04
FR2759906A1 (en) 1998-08-28

Similar Documents

Publication Publication Date Title
Asplund Nocturia: consequences for sleep and daytime activities andassociated risks
EA012964B1 (en) Pharmaceutical formulation of modafinil
RU2232016C2 (en) Isovaleramide as antispatic and anticonvulsant agent, extract from plant of valerianaceace family and hop as agent for treatment of spasticity symptom and method for elimination of this symptom, method for treatment of pathology eliminated by centrally-mediated reducing muscle tonus
JPS58134031A (en) Dihydrocyclosporin d for treating multiple screlosis
AU748993B2 (en) Pharmaceutical combinations containing tramadol
WO1998036744A1 (en) Use of milnacipran and its derivatives for preparing a medicine for treating certain psychiatric diseases
JP2003519181A (en) Methods and formulations for treating resistance to antihypertensives and related conditions
JPH10512573A (en) Combination agent for treating migraine and other diseases, comprising sesquiterpene lactone and vitamin B complex
US4987127A (en) Method of treating a virus outbreak
RU2560840C2 (en) Method of treating insomnia
US20060251731A1 (en) Therapeutic herbal lozenge composition
Ananth et al. Propranolol in psychiatry: therapeutic uses and side effects
Jensen et al. Clinical trial of nimodipine for single attacks of classic migraine
Friedman Part 1: Migraine headaches
BE1009060A3 (en) Pharmaceutical composition and method for their preparation.
Pelz et al. A case of pre-chronic paroxysmal hemicrania
TWI323174B (en) Topical pharmaceutical composition for prevention and treatment of premature ejaculation and/or hypersensitivity of sexual stimulation
WO1997044045A1 (en) Malatonin in combination with analgesics
RU2174005C1 (en) Species of medicinal herbs for treatment of neuroses and neurasthenia
RU2222329C2 (en) Treatment of depression and pharmaceutical preparations applied for this purpose
CA2839901A1 (en) Homeopathic compositions for treating back, sciatic, or lumbar pain
EP0402208A1 (en) Mixture of Vitamin A in physiological dosis and different active ingredients having therapeutic effect
RU2182016C2 (en) Spasmolytic composition, method to obtain spasmolytic composition
BIRNBAUM Peptic ulcer and the central nervous system—aetiology and management
RU2200550C2 (en) Novel medicinal forms of dimocifon in leprosy therapy, itching and allergodermatosis, during's dermatitis herpetiformis

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU BR CA CN JP KR MX NZ US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: PAT. BUL. 34/98 UNDER (54) AND (57) REPLACE "MINALCIPRAN" BY "MILNACIPRAN"

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1998536328

Format of ref document f/p: F

122 Ep: pct application non-entry in european phase